Syngene Thematic ADC WP

News

Dosing commences in Bio-Thera’s Phase I solid tumour study of BAT8013

The Phase I trial aims to determine maximum tolerated dose, evaluate pharmacokinetics, and gather preliminary efficacy data.

Salong Debbarma

News

BioNTech and DualityBio report positive data for trastuzumab pamirtecan

News

Daiichi Sankyo and AstraZeneca’s Enhertu gains NMPA approval for HER2 GEJ

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

Sections

Sections

Sections

Sections

Sections

Sections

Dosing commences in Bio-Thera’s Phase I solid tumour study of BAT8013

BioNTech and DualityBio report positive data for trastuzumab pamirtecan

Daiichi Sankyo and AstraZeneca’s Enhertu gains NMPA approval for HER2 GEJ

Leading VR Medical Training Software for Hospitals

Payers in the Healthcare Industry

Sign up for our daily news round-up!

Sign up to the newsletter: In Brief

Dosing commences in Bio-Thera’s Phase I solid tumour study of BAT8013

BioNTech and DualityBio report positive data for trastuzumab pamirtecan

Daiichi Sankyo and AstraZeneca’s Enhertu gains NMPA approval for HER2 GEJ

Sign up for our daily news round-up!

Sign up for our daily news round-up!

Sign up to the newsletter: In Brief

I would also like to subscribe to:

Thank you for subscribing